The health secretary, Jeremy Hunt, has asked the competition watchdog to look at claims that drug companies are exploiting the NHS to raise the price of medicines.
Hunt called in the Competition and Markets Authority (CMA) after aninvestigation by the Times suggested that prices have been vastly increased as the result of a loophole in NHS rules.
A health department spokesman said: “These are serious allegations and no pharmaceutical company should be exploiting the NHS. The secretary of state has asked the CMA to urgently look at the evidence uncovered by the Times as part of their continuing investigations into excessive drugs pricing.”
The Times investigation suggests suppliers are able to introduce “extortionate” price rises by dropping the brand name and taking the medicines outside NHS profit controls. The Times says the companies face limited competition on long-established, off-patent drugs, which they bought from large pharmaceutical companies. They allege that wholesalers and their customers also receive a cut and that the prices of 32 drugs have risen by more than 1,000% in the past five years.
The CMA can impose tough financial penalties on a company that is found to have charged excessive prices. The health department can recover losses through the courts.
Full Content: The Guardian
Want more news? Subscribe to CPI’s free daily newsletter for more headlines and updates on antitrust developments around the world.
Featured News
EU Extends Support for Farms and Fisheries Amid Market Disruptions
May 5, 2024 by
CPI
Sony and Apollo Bid $26 Billion for Paramount Acquisition
May 5, 2024 by
CPI
Goldman Sachs Resolves Decade-Old Metal-Rigging Class Action Lawsuit
May 5, 2024 by
CPI
Italian Antitrust Ruling Puts Halt on Intesa Sanpaolo’s Fintech Ambitions
May 5, 2024 by
CPI
Google Antitrust Case: Closing Arguments Conclude
May 5, 2024 by
CPI
Antitrust Mix by CPI
Antitrust Chronicle® – Economics of Criminal Antitrust
Apr 19, 2024 by
CPI
Navigating Economic Expert Work in Criminal Antitrust Litigation
Apr 19, 2024 by
CPI
The Increased Importance of Economics in Cartel Cases
Apr 19, 2024 by
CPI
A Law and Economics Analysis of the Antitrust Treatment of Physician Collective Price Agreements
Apr 19, 2024 by
CPI
Information Exchange In Criminal Antitrust Cases: How Economic Testimony Can Tip The Scales
Apr 19, 2024 by
CPI